An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Percutaneous Coronary Intervention

INCLUSION CRITERIA * Male or non-pregnant female greater than or equal to 18 years of age * Undergoing non-emergent single or multiple sites/vessels PCI during the same procedure * PCI to be performed with a femoral approach EXCLUSION CRITERIA * Known or suspected pregnancy in women of childbearing potential * Thrombolytic therapy within the previous 24 hours * Undergoing primary PCI for ongoing ST-segment elevation myocardial infarction (STEMI) * Undergoing rescue PCI after failed thrombolysis * Any other elective PCI scheduled within the following 30 days after the index PCI * Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, intracranial tumor or aneurysm; recent (\<1 month) trauma or major surgery (including bypass surgery); active bleeding * Uncontrolled arterial hypertension * Recent (\<48 hours) or planned spinal/epidural anesthesia or puncture * Impaired haemostasis: known International Normalized Ratio (INR) \>1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µL) * History of hypersensitivity or contraindication to heparin or LMWH * Treatment with oral anticoagulant therapy within 72 hours prior to inclusion or current need for vitamin-K antagonist therapy * Treatment with a direct thrombin inhibitor, low molecular weight heparin, or unfractionated heparin within the 24 hours preceding enrolment * Use of abciximab within the previous 7 days or, tirofiban, or eptifibatide within the past 12 hours of index PCI * Inability to give informed consent or high likelihood of being unavailable for follow-up * Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrollment in this trial